A Phase 4 interventional study of Ropivacaine injection in Anesthesia, Local, sponsored by Zealand University Hospital. Status unknown at 1 site in Denmark. Open to male participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-03.
Sponsored by Zealand University Hospital · Phase 4, Interventional, and Treatment
The intertransverse process (ITP) block is a new ultrasound-guided peripheral nerve block modality designed for peri- and postoperative pain amelioration for patients undergoing surgery on the thoracic wall. The modality mimics the well-known thoracic paravertebral block but, potentially, with a significantly lower risk of adverse events. However, evidence for the ITP block efficacy and the clinical applicability, e.g. the number of injections, dermatomal coverage etc., is still sparse and needs further investigation.
In this noninferiority, short-term, randomised, blinded, procedure-related crossover trial we will further investigate the ITP block in healthy volunteers to see whether it is possible to reduce the number of injections from three to one and substantiate the number of anaesthetised dermatomes with either modality as the primary outcome. Secondary outcomes include sensory mapping of the thorax, non-invasive thermography, changes in non-invasive blood pressure and satisfaction with block application.
At Zealand University Hospital, twelve healthy volunteers will be randomised to receive either a single injection or multiple injection blockade with long-lasting local anaesthetic. All twelve participants will, on day one, receive active blockade with the well-known marketed drug Ropivacaine 7.5mg/ml, and all participants will receive 21 ml; that is six participants receiving 1x21ml and six participants receiving 3x7ml. The six participants receiving 1x21 ml will also receive two sham injections to ensure the blinding. No placebo is used. On day two the intervention is crossed over and the participants will receive the other modality. Within the following hour after block application, relevant standard cutaneous testing is performed; pinprick and cold sensation test for dermatomal coverage, the anaesthetised skin area is pen marked on the thorax and photo documented, thermography to measure temperature differences between each hemi thorax (blocked side vs. non- blocked side) and standard non-invasive blood pressure measurements are performed.
After 60 minutes of relevant testing the trial ends and the participant are free to leave the hospital 2 hours after block application if no adverse events are recorded. With such series of test procedures, we will generate new knowledge of the ITP block before future patients undergo breast cancer surgery.
Zealand University Hospital is the lead sponsor of 234 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Male sex Age ≥ 18 years at the date of inclusion American Associations of Anaesthesiologist (ASA) class I-II Have received thorough information, orally and in written form, and signed the "Informed Consent" form on participation in the study.
Weight > 52,5 kilograms (chosen due to the international maximal single dose of Ropivacaine (3mg/kg))
Exclusion Criteria:
1x21ml Ropivacaine (7.5mg/ml) at ITTC T4. Including two sham injections at ITTC T2 and ITTC T6
Drug: Ropivacaine injection
3x7ml Ropivacaine (7.5mg/ml) at ITTC T2, T4 and T6.
Drug: Ropivacaine injection
We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
Anesthetized thoracic dermatomes.
The primary outcome of this procedure related study is the number of anesthetized thoracic dermatomes. Key points of sensory testing will follow International Standards for Neurological Classification of Spinal Cord Injury. Dermatomal spread of the single- and multiple-injection ITP blocks will be determined using both mechanical (pinprick) and temperature (cold) discrimination, deficit for either modality is regarded as a sensory deficit.
Time frame: Minute 35 post block application.
Sensory mapping.
The extent of cutaneous spread of the sensory block (single vs multiple-injection ITP block). Spread of the single- and multiple-injection ITP blocks respectively will be determined using both mechanical (pinprick) and temperature (cold) discrimination, deficit for either modality is regarded as a sensory deficit. Relevant areas are marked on the participants' thoraxes and transferred to paper for conversion to square centimeters.
Time frame: Minute 45 post block application.
Thermography in a clinical setup.
A peripheral nerve block leads to a motor and somatosensory blockade but also sympathetic nerve fibers are being blocked. The following sympatholysis increases the diameter of the vessels (vasodilatation) in the skin and thereby increasing the blood flow and increases the temperature. Hence, it is possible that the technique would help determine the expected success of the blockade in a fast and efficient manner. We will use the "Testo 883 Thermography camera" (Testo SE \& Co. KGaA, Lenzkirch, Baden-Württemberg, Germany) to obtain infrared imaging of the anterior thorax of the participants. Each thoracic dermatome from T2-T10 will be evaluated in the mid-clavicular line and reported as the temperature difference when compared to the contralateral side.
Time frame: Minutes 10, 20 and 30 post block application
Non-invasive blood pressure.
Standard non-invasive blood pressure measurement reported as mean arterial pressure.
Time frame: Minutes 15, 30 and 60 post block application.
Block application satisfaction.
The Numeric Rating Scale (NRS) for pain scores is a well-known clinical scale. It ranges 0-10, 0 being no pain and 10 being the worst pain imaginable. The participant will rate the block application NRS score orally during block application.
Time frame: During block application.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zealand University Hospital